首药控股2026年关注点：业绩增长与核心产品审评进展

Financial Performance - The company reported a revenue of 8.6676 million, representing a year-on-year increase of 119.88%, with losses narrowing compared to the previous year [2] Business Development - The NDA review for the core product SY-707 (Shouyaoze) for ALK-positive non-small cell lung cancer is progressing steadily, with supplementary materials submitted in November 2025 [3] - The NDA for SY-5007 (Shouyize) for RET fusion-positive non-small cell lung cancer was accepted in October 2025 and is currently under review, with clinical data presented at the 2025 ESMO annual meeting [3] - The key clinical trial for SY-3505 (Ficonalkib), a third-generation ALK inhibitor, has completed patient enrollment, and the company plans to submit the NDA after data readout [3] Product Development - The company is strengthening its early-stage projects, including MAT2A, ALK-4G, and p53Y220C, to advance more candidate drugs into clinical stages [4]